Indivior to pursue a change in domicile from the U.K. to the U.S

Indivior (INDV) announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. parent company, Indivior Pharmaceuticals, or IPI, above its existing U.K. parent company. This follows Indivior’s U.S. listing on the Nasdaq and subsequent cancellation of its secondary listing on the London Stock Exchange. Indivior’s board of directors is recommending the proposed change in domicile of the parent company of the Indivior group to maximize the benefits of its U.S. stock listing. Indivior intends to implement the redomiciliation by means of a U.K. court-sanctioned scheme of arrangement. Subject to the approval of Indivior’s shareholders, following the effectiveness of the Scheme, Indivior will become a direct wholly owned subsidiary of IPI, a new Delaware corporation. IPI’s common stock will be listed on Nasdaq and will continue to trade under the symbol INDV. Shareholders of Indivior PLC will receive one new IPI share for each Indivior PLC share held as of the scheme record date. Indivior PLC shares will be cancelled at the time shareholders receive their new shares of IPI. No additional equity will be raised by IPI as part of the transaction. The Scheme requires a formal vote by Indivior PLC shareholders at an extraordinary general meeting to be approved by a majority in number of Indivior PLC shareholders voting in person or by proxy and representing 75% in value of the shares voted. The timeline for the transaction is expected to be: Mid November 2025: Shareholder circular including the notice of EGM issued to shareholders; Early December 2025: EGM held in London; Late January 2026: Effective date of the Scheme; Indivior PLC shares exchanged for IPI shares; IPI shares begin trading on Nasdaq. No action is needed by shareholders at this time.